PCM
ADPT icon

Penserra Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Penserra Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$495K Buy
+23,102
New +$354K ﹤0.01% 581
2020
Q4 		– Sell
-1,158
Closed -$56K – 1004
2020
Q3 		$56K Buy
+1,158
New +$48.7K ﹤0.01% 616

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Penserra Capital Management's ADPT Position: Q2 2026 in Review

Penserra Capital Management opened a new position in Adaptive Biotechnologies (ADPT) in Q2 2026: 23,102 shares worth $495K. The stake represents ﹤0.01% of the portfolio and ranks #581 among its holdings. This is a return to the name: Penserra Capital Management previously reported a position in ADPT as recently as Q3 2020.

Penserra Capital Management first reported a position in ADPT in Q3 2020 and has held it in 2 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Penserra Capital Management held 23,102 shares of Adaptive Biotechnologies worth $495K as of Q2 2026.
  • Adaptive Biotechnologies was a new Penserra Capital Management position in Q2 2026.
  • Adaptive Biotechnologies made up ﹤0.01% of Penserra Capital Management's portfolio in Q2 2026, its #581 holding.
  • Penserra Capital Management first reported a position in Adaptive Biotechnologies in Q3 2020 and has held it in 2 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.